Brainreader’s core product, Neuroreader, is a CE-marked and FDA-cleared software platform that delivers automated volumetric analysis of brain MRI scans to aid radiologists and neurologists. The platform integrates into standard workflows to help detect subtle changes in brain structure faster and with greater precision. Neuroreader is used in clinical practice to support diagnosis and monitoring of Alzheimer’s disease, traumatic brain injury, and other neurodegenerative disorders. Brainreader plans to accelerate a global rollout and scale commercial operations, with particular focus on the US healthcare market. The company also intends to continue development of new features and clinical applications for its platform. Recent regulatory and reimbursement dynamics—US adoption of CPT codes for brain volumetry and EU MDR compliance—are cited as tailwinds for broader clinical adoption.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

May 2025